Kristen Williams
Known title: Chief Administrative OfficerCIK: 0001296965
Associated companies
Transaction History
| PCRX | ▼ Sell | Open Market | 10,259 | $228K | 6/4/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 8,528 | $190K | 6/3/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 54,546 | $0 | 2/11/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 13,137 | $270K | 2/2/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 17,134 | $352K | 1/30/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 14,376 | $377K | 6/4/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 6,162 | $163K | 6/3/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 79,200 | $0 | 2/1/2025 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,452 | $211K | 6/13/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 54,300 | $0 | 6/12/2024 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 3,011 | $93K | 6/3/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 33,700 | $0 | 2/5/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 10,950 | $0 | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 6,467 | $239K | 6/14/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,357 | $51K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,301 | $51K | 6/6/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 9,900 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 4,649 | $277K | 6/7/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 3,969 | $244K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,953 | $113K | 3/21/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,112 | $92K | 3/21/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,188 | $104K | 3/21/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,253 | $527K | 3/21/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,050 | $79K | 2/25/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 50 | $3K | 2/25/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,000 | $134K | 2/25/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 10 | $384 | 2/16/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 10 | $650 | 2/16/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 800 | $31K | 2/10/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 800 | $52K | 2/10/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 1,000 | $38K | 2/4/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,000 | $65K | 2/4/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 200 | $8K | 1/21/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 200 | $13K | 1/21/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,199 | $144K | 1/19/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,199 | $84K | 1/19/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 1,375 | $61K | 1/18/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 2,600 | $100K | 1/18/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 6,338 | $276K | 1/18/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 13,127 | $626K | 1/18/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 23,040 | $1.5M | 1/18/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 400 | $26K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.